cystathionine /3-synthase activity in synthase-deficient homocystinuric patients have been only partially successful. All such studies, however, have been conducted with extracts of cultured skin fibroblasts grown in medium containing a high concentration (1,000 ng/ml) of pyridoxal. Having recently shown that such growth conditions may obscure important aspects of enzyme-coenzyme interactions by saturating most synthase molecules with their cofactor, pyridoxal 5'-phosphate, we have established conditions for growth of cells in pyridoxal-free medium. Under these conditions, intracellular pyridoxal 5'-phosphate fell by >95%, and saturation of cystathionine 83-synthase apoenzyme with pyridoxal 5'-phosphate decreased from a predepletion value of 70% to <10%. When such depleted cells were grown in media containing pyridoxal concentrations ranging from 0 to 1,000 ng/ml, cellular pyridoxal 5'-phosphate reached a maximum of 30 ng/mg cell protein at a medium pyridoxal concentration of 100 ng/ml. Maximal saturation of aposynthase with coenzyme in control cells was reached at a medium pyridoxal concentration of 10 ng/ml. In contrast, maximal saturation of residual aposynthase in cells from an in vivo responsive patient was achieved at a medium pyridoxal concentration of 25-50 ng/ml, whereas that from cells from an in vivo unresponsive patient was reached at 100 ng/ml. Estimates ofthe affinity ofcontrol and mutant cystathionine f8-synthase for pyridoxal 5'- phosphate in cell extracts supported the differences observed in intact cells. The apparent Km of cystathionine /3-synthase for pyridoxal 5'-phosphate in extracts of depleted cells from four in vivo-responsive patients was two to four times that of control. In contrast, the Km for pyridoxal 5'-phosphate in two lines from in vivo
INTRODUCTION
Homocystinuria caused by deficiency of cystathionine ,/-synthase (CS)1 is a well-recognized, autosomal recessively inherited inborn error of sulfur amino acid metabolism. The major clinical manifestations of this disorder include dislocated optic lenses, thrombotic vascular disease, and mental retardation. The most prominent biochemical abnormalities in affected patients are elevated plasma and urinary concentrations of methionine and homocystine, and a much reduced plasma cystine (1) . CS (L-serine hydro-lyase [adding homocysteine], EC 4.2.1.22) requires pyridoxal 5'-phosphate (PLP) as a coenzyme. Consequently, many affected patients have been treated with large doses of oral pyridoxine, the vitamin precursor of PLP. In about half of such individuals, sulfur amino acid concentrations in blood and urine have returned to near normal levels. Such patients are classified as in vivo pyridoxine-responsive (2) . All attempts to correlate such in vivo responsiveness with stimulation of residual CS activity by PLP in vitro have been less than successful. Uhlendorf et al. (3) found that in vivo responsiveness or nonresponsiveness correlated generally with 1Abbreviations used in this paper: C, control; CS, cystathionine 8-synthase; MEM, minimal essential medium; N, in vivo nonresponsive; PL, pyridoxal; PLP, pyridoxal 5'-phos-the presence or absence, respectively, of some residual CS activity in extracts of cultured fibroblasts. Several in vivo nonresponsive patients have been described, however, whose cells retained some residual CS activity (3, 4) . Kim and Rosenberg (5) reported that CS in fibroblast lines from several in vivo responsive patients was more thermolabile than normal, and had a reduced affinity for PLP. Increased thermostability and enhanced catalytic activity were observed in the presence of saturating amounts of the coenzyme. On the basis of these findings, they proposed that in vivo pyridoxine responsiveness depended on the quality as well as the quantity of residual enzyme. Exceptions to this thesis were reported in that stimulation of residual CS activity by PLP in vitro was sometimes as great in cells from in vivo unresponsive patients as from responsive ones (3, 4) , and in that apparent Km of CS for PLP were not reproducibly elevated in cells from responsive patients (4 Conditions for depletion and repletion. Skin fibroblasts were grown to confluence in Eagle's MEM containing 1,000 ng/ml PL and hydroxylamine-treated human serum. They were then transferred to vessels containing medium with no added PL anid hydroxylamine-treated human serumn, and grown to conifluenice for one or two passages. The PLP-depleted cells were then used for two kinds of estimiates of affinity of CS for PLP: first, in which CS activity was determined in cell extracts after repletion experimenits in medium containing increasing concentrations of PL; second, in which CS activity was measured in cell extracts as a function of PLP conicenltration added in vitro.
Cell extr(acts. Cells vere grown to confluence (3-6 d after subculture), then harvested with 0.1% trypsini solution, washed twice with phosphate-buffered satlinie (pH 7.4), and then stored ais cell pellets at -80°C until assayed. Cell extracts were prepared by sonicationi in 0.05 M potassium phosphate buffer, pH 7.5, containiing 1 mM 8-mereaptoethanol. The superniate olbtained after centrifugation at 10,000 g for 10 min at 4°C w-,as used for enzymllatic and PLP assavs.
En.zyme assayt. CS activity was assayed as described by Fowler et al]. (4) . "Holoenzyme" vas quantitated by aissaying in the absence of added PLP, whereas "total" enzyme was meassure(l in the presence of 1 mM PLP. A Alech/anism for Pyiridoxine-responsive Honmocystinuria (Norwalk, Conn.) using 300 1il of sample. Excitation was at 320 nm and emission at 420 nm. For each assay, PLP standards containing 1-50 ng of PLP were included. In. addition, known quantities of PLP were added to extracts to determine recovery.
RESULTS
CS activity in control and CS-deficient fibroblast lines. Results of multiple determinations of CS activity in extracts of cells grown in standard PL supplemented (1,000 ng/ml) medium are summarized in Table I Fig. 2 (which Cells were initially grown to confluence in Eagle's MEM containing 1,000 ng PL/ml and hydroxylamine-treated human serum. They were then subcultured and grown in medium containing no PL and hydroxylamine-treated human serum for four additional passages. CS activity was assayed after each passage in cell extracts with (total enzyme) and without (holoenzyme) in vitro addition of 1 mM PLP. Intracellular PLP was determined fluorometrically. +, growth in medium containing PL at 1,000 ng/ml; -, growth in medium containing no PL. transferred for one passage into flasks containing media with concentrations of PL ranging from 0 to 1,000 ng/ml. Such additions of PL to the growth medium led to a rapid increase in cellular PLP content both in control and CS-deficient cells as shown in Fig. 3A . Maximal cellular PLP content was reached at a medium PL concentration of 100 ng/ml; a further 10-fold increase in medium PL concentration did not lead to a further increase in intracellular PLP. The associated response of control and mutant CS aposynthase to increases in PL concentration in the growth medium and in cellular PLP content is illustrated in Fig. 3B . A clear difference can be seen between the control and mutant lines, and also between the response of in vivo responsive (R)-676 and in vivo nonresponsive (N)-375. CS holoenzyme activity in the control line roughly paralleled the rise in cellular PLP, reached its maximum value at a PL concentration in the medium of 10 ng/ml, and plateaued thereafter.
The representative mutant cells, however, behaved quite differently. R-676 had no measurable CS holoenzyme at 1 ng/ml of PL; appreciable holoenzyme was noted only at a PL concentration of 10 ng/ml or more. Holoenzyme activity then increased progressively and reached a maximal value at a medium PL concentration of 25-50 ng/ml. The detected below a PL concentration of 10 ng/ml, and maximal activity was seen only at 100 ng PL/ml medium. It is noteworthy that CS holoenzyme did not increase further in either mutant line when the PL concentration was increased above 100 ng/ml, that concentration which produced maximal augmentation of cellular PLP content. When the holoenzyme activities shown in Fig. 3B are expressed as a percent of total enzyme, that is, as an index of aposynthase saturation with PLP, the distinct differences between the lines were again clear (Fig. 4) . The control line retained significant holoenzyme activity after PLP depletion, whereas the mutants had none; maximal saturation of control aposynthase with PLP (70% of total) was reached at 10 ng PIJml. In both mutant lines, the maximal extent of CS saturation with PLP and the medium PL content at which such saturation was achieved were altered. In line R-676, holoenzyme never exceeded 38% of total, and this degree of saturation was achieved at medium PL concentrations of 25-50 ng/ml. In line N-375, holoenzyme reached only 19% oftotal, and then only at 100 ng PL/ml. No conversion of remaining CS apoenzyme to active holoenzyme was observed in either mutant line beyond that achieved at the medium PL concentration (100 ng/ml) at which the cellular PLP content reached its maximum.
DISCUSSION
The less than satisfactory correlation in CS-deficient homocystinuria between the biochemical response of the patient to orally administered pyridoxine and the response of that patient's CS activity in cell extracts to PLP has puzzled investigators in the field. We have shown recently (6) that the large excess of PL present in the standard growth medium results in a maximal intracellular PLP content and full saturation of certain PLP-dependent enzymes, including CS. Thus, interpretation of studies aimed at defining the affinity of CS for PLP in cells grown under these conditions is exceedingly difficult. Our previous attempts (4) to resolve PLP from mutant CS holoenzyme with hydroxylamine in vitro were largely unsuccessful as a result of the instability of the mutant enzymes. We have, therefore, established conditions for depleting fibroblast cells of PLP "in culture" by growing them in PL-free medium. Cell viability during several passages in this medium was judged normal on the basis of several criteria (6) . Our results show that, To determine whether these in vitro Km estimates bore some relationship to events in intact cells, we grew PLP-depleted cells from representative control, responsive, and nonresponsive patients in media containing pyridoxal concentrations from 0 to 1,000 ng/ml, and we estimated PLP content and synthase activity in extracts therefrom. The results showed that holoenzyme formation in the line from the responsive patient occurred at a much higher PL concentrationi in the medium than that needed for formation of holoenzyine in the control cells, but much lower than that observed for cells of the nonresponsive patient. Furthermore, in the in vivo responsive patient, 38% of synthase activity existed as holoenzyme maximally, whereas in the in vivo nonresponsive sub)ject, only 19% of CS molecules were converted to holoenzyme at maximum levels of PLP in the cells.
When the in vitro kinetic and PLP-repletion data are interpreted together, we believe both the affinity of CS for PLP and the cell's ability to accumulate PLP assume importance in understanding in vivo responsiveness to oral pyridoxine in CS-deficient patients. We suggest that in vivo responsiveness or lack thereof depends on at least three factors: (a) the presence or absence of residual synthase activity in mutant cells; (b) the affinity of mutant synthase for its cofactor, PLP; and (c), as importantly, the cell's ability to accumulate PLP. We propose that those patients whose cells contain a mutant synthase with a moderately reduced affinity for PLP (perhaps two to five times less than control) are able to increase cellular PLP content sufficiently after pyridoxine supplementation so that holosynthase activity rises above that critical value needed to prevent accumulation of homocystine and methionine. Pyridoxine nonresponsiveness, on the other hand, may be observed for one of two general reasons: either because the cell contains no residual synthase activity (a situation which appears to exist in most nonresponsive patients), or because the cell conitains a mutant synthase whose affinity for PLP is so reduced (perhaps 20-70 times less than control) that, despite any feasible pyridoxine supplements, the cell is unable to increase PLP content enough to stiinulate appreciable formation of synthase holoenzyme. In this sttudy we demionstrate that the fibroblast cell will not accumulate PLP above a certain limit (-30 ng PLP/mg cell protein at 50-100 ng PL/ml medium) even though the PL concentration in the culture medium is increased to 1,000 ng/ml. It has also been shown that the hepatic content of PLP is controlled principally by the protein binding of this coenzyme and its hydrolysis by a cellular phosphatase. When the amount of PLP exceeds the binding capacity of intracellular proteins and apoenzymes, free PLP is hydrolysed by plasma membrane-associated alkaline phosphatase (9) . When cell extracts are prepared and these cellular barriers are obviated, much higher concentrations of PLP can be added, thereby creating the possibility that cells from an in vivo nonresponsive patient may be "responsive" in vitro. This caveat must be kept in mind in attempting to correlate events in intact cells or whole patients with those in cellfree extracts.
